A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
Phase 1
18–60
5 sites in CA, FL, MO +1
What this study is about
This Phase 1 study is focused on people with healthy volunteers. The primary outcome being measured is Number of Participants Who Discontinue Study Treatment Due to an AE.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: Apparent Clearance (CL/F) of MK-4082, Apparent Terminal Half-life (t1/2) of MK-4082, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Body Weight, Maximum Plasma Concentration (Cmax) of MK-4082, Time to Maximum Plasma Concentration (Tmax) of MK-4082